secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition II Corp. (DMII)
CIK:        0002040475
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001213900-26-048687
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Drugs Made In America Acquisition II Corp. updates CFO and CEO compensation, grants equity upon business combination
--------------------------------------------------------------------------------

- CFO Saleem Elmasri's monthly fee remains $3,500; equity grant increases from 100,000 to 175,000 shares earned at execution of definitive agreement.
- CEO Roger Bendelac receives $4,500/month ($2,500 current, $2,000 deferred) and 250,000 shares earned upon signing a definitive business combination agreement.
- Both equity grants are to be issued at closing of the initial business combination, within ten days thereafter.
- Updated Statement of Work with Titan Advisory Services LLC and CEO Compensation Agreement with Aleutian Equity Holdings LLC were entered on April 22, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026048687/0001213900-26-048687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026048687/ea0287975-8k_drugs2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-048687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer